Search alternatives:
μ decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
n decrease » nn decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
10 μ » 10 _ (Expand Search)
50 c » 5 c (Expand Search), 50 μ (Expand Search), 50 _ (Expand Search)
50 n » 50 ns (Expand Search), 50 ng (Expand Search), 50 μ (Expand Search)
μ decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
n decrease » nn decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
10 μ » 10 _ (Expand Search)
50 c » 5 c (Expand Search), 50 μ (Expand Search), 50 _ (Expand Search)
50 n » 50 ns (Expand Search), 50 ng (Expand Search), 50 μ (Expand Search)
-
1
-
2
GSK343 decreased tumor stemness.
Published 2021“…(C) COA6 cells were treated with GSK343 (0, 5 μM) for 72 hours. qPCR demonstrated a significant decrease in mRNA abundance of known stemness markers Oct4, Nanog, and Sox2 following GSK343 treatment compared to untreated cells. …”
-
3
-
4
mGluR5 receptor decreased glycinergic currents.
Published 2019“…(<b>E</b>) The inhibitory effect of CHPG on GlyR-IPSCs was not blocked by intracellularly loaded GDP-β-S (62.3 ± 6.4% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.782, <i>p</i> = 0.032), chelerythrine (60.9 ± 11.3% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.705, <i>p</i> = 0.035), or Ro-32-0432 (69.9 ± 3.2% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 8.495, <i>p</i> < 0.001). (<b>F</b>) Postsynaptic loading of U-0126 or PD98059 prevented CHPG from decreasing glycinergic responses (U-0126, 107.6 ± 10.4% of baseline at 15–20 min post-CHPG, <i>t</i>[8] = 0.997, <i>p</i> = 0.348; PD98059, 93.1 ± 5.0% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 0.883, <i>p</i> = 0.418). …”
-
5
-
6
-
7
-
8
TUDCA decreases ER stress in HOX neonatal rat lungs.
Published 2022“…<p>(<b>A</b>) The expression levels of ER stress markers (P-PERK 0.6±0.1-fold, p<0.001, n = 5; PERK 0.7±0.1-fold, p = 0.00364, n = 5; P-IRE1α 0.6±0.0-fold, p<0.001, n = 5; IRE1α 0.6±0.1-fold, p<0.001, n = 5; GRP78 0.8±0.1-fold, p<0.001, n = 5; cleaved ATF6 0.1±0.0-fold, p<0.001, n = 5; spliced XBP1 0.3±0.0-fold, p<0.001, n = 5; 2 males and 3 females) are all decreased while the N-glycosylated VEGFR2 is increased (3.5±0.2-fold, p<0.001, n = 5) in HOX neonatal lungs at P10 indicating TUDCA can attenuate hyperoxia-induced ER stress. …”
-
9
The GluN2B-C456Y mutation decreases recombinant NMDAR currents and alters receptor properties.
Published 2020“…Note that the amount of the mutant currents is <1% of the WT currents, despite the fact that mutant currents were recorded 1 day later than WT (3 and 2 days following oocyte injection, respectively). <i>n</i> = 73 oocytes for WT (5.70 ± 0.61 μA) and 59 oocytes for C456Y (0.039 ± 0.004 μA), ***<i>P</i> < 0.001, Mann-Whitney. …”
-
10
FTY720 treatment decreased tumor growth in a xenograft model of hepatoblastoma.
Published 2019“…When tumors reached an average of 150 mm<sup>3</sup>, mice were randomized to receive vehicle (ORA-Plus, 50 μL, n = 7) or FTY720 (10 mg/kg body weight/day in ORA-Plus, 50 μL, n = 7) by oral gavage for 16 days. …”
-
11
-
12
The decrease or inhibition of Hsp90 induced REST degradation.
Published 2019“…(D) The level of REST dramatically reduced in differentiated SH-SY5Y cells treated with GA (1 μM) or PU-H71 (50 nM) at 24 h. …”
-
13
-
14
-
15
-
16
-
17
-
18
-
19
Downregulation of DOM decreases the abundance of PER and TIM.
Published 2019“…Downregulation of DOM decreased PER levels at CT1-5 and CT17-21. (Scale bar: 50 um.) …”
-
20